Literature DB >> 10465064

Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.

D P Brooks1, R R Ruffolo.   

Abstract

Systolic hypertension is a major risk factor for cardiovascular disease. The determinants of systolic blood pressure are peripheral resistance and arterial compliance. Arterial vasoconstriction, vascular growth and fluid retention, induced by the renin-angiotensin system directly or indirectly by enhancing sympathetic nervous system activity, are important factors in increasing peripheral resistance, decreasing arterial compliance and, consequently, elevating systolic blood pressure. Selective blockade of the angiotensin II type 1 (AT1) receptor represents a novel mechanism for interrupting the renin-angiotensin system. This provides the additional benefit of blocking angiotensin II generated by non-angiotensin-converting-enzyme pathways without altering either bradykinin metabolism or the potential beneficial effects of AT2 receptor stimulation. Eprosartan is a potent (1.4 nmol/l) AT1 receptor antagonist that inhibits angiotensin-II-induced vascular contraction in a competitive manner. Eprosartan is effective in reducing disease progression in animal models of hypertension, heart failure, renal disease and stroke. Furthermore, eprosartan causes a large increase in arterial compliance in hypertensive rats fed high-salt and high-fat diets. Eprosartan also possesses sympathoinhibitory activity as demonstrated by an inhibition of the pressor responses induced by activation of sympathetic outflow through spinal cord stimulation in pithed rats. In contrast, other angiotensin II receptor antagonists, such as losartan, used at equivalent angiotensin II blocking activity, do not appear to alter sympathetic nervous system activity. Angiotensin II receptor antagonists, such as eprosartan, that have the ability to block both the direct effects of angiotensin II and the indirect effects mediated by enhanced sympathetic neurotransmission, may represent an important advance in the treatment of elevated systolic blood pressure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465064

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  7 in total

Review 1.  Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.

Authors:  H Krum
Journal:  Curr Hypertens Rep       Date:  2001-09       Impact factor: 5.369

2.  MAPK and angiotensin II receptor in kidney of newborn rats from losartan-treated dams.

Authors:  Ana Paula Coelho Balbi; Evelyn Cristina Santana Marin; Heloisa Della Coletta Francescato; Roberto Silva Costa; Terezila Machado Coimbra
Journal:  Pediatr Nephrol       Date:  2008-06-04       Impact factor: 3.714

3.  Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.

Authors:  George Suzuki; Takayuki Mishima; Elaine J Tanhehco; Victor G Sharov; Anastassia Todor; Sharad Rostogi; Ramesh C Gupta; Pervaiz A Chaudhry; Petros V Anagnostopoulos; Omar Nass; Sidney Goldstein; Hani N Sabbah
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

4.  High fat diet confers vascular hyper-contractility against angiotensin II through upregulation of MLCK and CPI-17.

Authors:  Jee In Kim
Journal:  Korean J Physiol Pharmacol       Date:  2016-12-21       Impact factor: 2.016

Review 5.  Clinical profile of eprosartan: a different angiotensin II receptor blocker.

Authors:  P J Blankestijn; H Rupp
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-10

Review 6.  Endothelial effects of antihypertensive treatment: focus on irbesartan.

Authors:  Roberto Negro
Journal:  Vasc Health Risk Manag       Date:  2008

7.  Angiotensin receptor blockade with Losartan attenuates pressor response to handgrip contraction and enhances natriuresis in salt loaded hypertensive subjects: a quasi-experimental study among Nigerian adults.

Authors:  Francis Muyiwa Agbaraolorunpo; Olusoga Adekunle Sofola; Chikodi Nnanyelu Anigbogu; Elaine Chinyelu Azinge
Journal:  Pan Afr Med J       Date:  2019-12-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.